Pfizer Inc. $PFE Stock Position Lifted by Phoenix Financial Ltd.

Key Points

• Phoenix Financial Ltd. increased its stake in Pfizer by 67.3% in Q2, owning 76,603 shares valued at approximately $1.86 million.
• Pacer Advisors Inc. also significantly boosted its holdings in Pfizer by 856.8%, acquiring over 20 million shares worth about $508 million.
• Pfizer reported a 10.3% year-over-year revenue increase for Q2, with earnings per share beating expectations, and plans a dividend payout of $0.43 per share in December.

Phoenix Financial Ltd. grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 67.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,603 shares of the biopharmaceutical company's stock after buying an additional 30,805 shares during the period. Phoenix Financial Ltd.'s holdings in Pfizer were worth $1,856,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its holdings in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi lifted its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new stake in shares of Pfizer in the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. lifted its holdings in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PFE shares. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.13.

Pfizer Stock Up 0.6%

Shares of PFE stock opened at $24.84 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.17. The stock has a market cap of $141.23 billion, a PE ratio of 13.21, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The business's fifty day moving average is $24.89 and its 200-day moving average is $24.13. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.